HCA Healthcare And Grail Collaborate To Advance Comprehensive Cancer Care With Multi-Cancer Early Detection Screening
Portfolio Pulse from Benzinga Newsdesk
HCA Healthcare, Inc. (NYSE:HCA) and GRAIL, LLC have announced a strategic collaboration to advance comprehensive cancer care through early detection. GRAIL's Galleri multi-cancer early detection (MCED) test will be available to patients who meet screening criteria at select HCA Healthcare physician practices. The Galleri test can detect a shared cancer signal across more than 50 types of cancers using a simple blood draw. HCA Healthcare is also participating in the PATHFINDER 2 multi-center interventional study of the Galleri test.
October 17, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HCA Healthcare has partnered with GRAIL to offer the Galleri multi-cancer early detection test at select HCA Healthcare physician practices. This could potentially increase patient volume and improve patient outcomes.
The partnership with GRAIL allows HCA Healthcare to offer a cutting-edge cancer detection test, which could attract more patients to their practices and improve patient outcomes through early detection. This could potentially lead to increased revenues for HCA Healthcare.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Although Illumina (ILMN) is not directly mentioned in the article, it is the parent company of GRAIL. The partnership between HCA Healthcare and GRAIL could potentially benefit Illumina.
As the parent company of GRAIL, Illumina could potentially benefit from the partnership between GRAIL and HCA Healthcare. The increased use of GRAIL's Galleri test could lead to increased revenues for Illumina.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50